KLONOPIN RAPIDLY DISINTEGRATING Drug Patent Profile

Which patents cover Klonopin Rapidly Disintegrating, and what generic alternatives are available?

Klonopin Rapidly Disintegrating is a drug marketed by Roche and is included in one NDA.

The generic ingredient in KLONOPIN RAPIDLY DISINTEGRATING is clonazepam. There are ten drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the clonazepam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Klonopin Rapidly Disintegrating

A generic version of KLONOPIN RAPIDLY DISINTEGRATING was approved as clonazepam by TEVA on September 10^th, 1996.

Summary for KLONOPIN RAPIDLY DISINTEGRATING

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,178
DailyMed Link:	KLONOPIN RAPIDLY DISINTEGRATING at DailyMed

US Patents and Regulatory Information for KLONOPIN RAPIDLY DISINTEGRATING

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-001	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-004	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-002	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-003	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-005	Dec 23, 1997		DISCN	Yes	No

Expired US Patents for KLONOPIN RAPIDLY DISINTEGRATING

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-003	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-001	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-004	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-004	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-005	Dec 23, 1997

International Patents for KLONOPIN RAPIDLY DISINTEGRATING

See the table below for patents covering KLONOPIN RAPIDLY DISINTEGRATING around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	633717	Moulded carrier for chemicals and/or pharmaceuticals
Mexico	195411	ARTICULOS MOLDEADOS SOLIDOS Y PROCEDIMIENTO PARA SU PREPARACION.
Austria	27058
Algeria	481	Produit manufactures façonnes solides.
Ireland	822663

Market Dynamics and Financial Trajectory for Klonopin Rapidly Disintegrating

Last updated: July 29, 2025

---

Introduction

Klonopin Rapidly Disintegrating (clonazepam RDT) represents an innovative formulation of clonazepam intended for improved patient compliance and convenience, especially for populations with swallowing difficulties or adherence challenges. As a rapidly disintegrating sublingual or oral disintegrating tablet, this formulation introduces nuanced market dynamics significantly impacting its adoption, competitive positioning, and long-term financial prospects within the global pharmaceutical landscape.

---

Market Overview

The global benzodiazepine market, within which Klonopin (clonazepam) operates, is experiencing steady growth driven by increasing prevalence of neurological and psychiatric disorders such as epilepsy, anxiety, and panic disorders [1]. The rapid disintegration formulation aims to capitalize on evolving consumer preferences for convenience and faster onset of action, thus expanding the therapeutic application scope.

The introduction of Klonopin RDT aligns with pediatric, geriatric, and compliance-sensitive segments demanding formulations facilitating ease of administration [2]. Its potential to reduce inhalation injury risk and enhance bioavailability further underscores its market appeal.

---

Market Drivers

1. Demographic Shifts and Disease Prevalence

An aging global population increases the demand for benzodiazepines like clonazepam due to their efficacy in managing neurological disorders. Simultaneously, rising anxiety and panic disorder cases in younger cohorts contribute to expanding indications [3].

2. Enhanced Patient Compliance and Convenience

Rapid disintegration formulations simplify medication intake, particularly for children and elderly patients with dysphagia. Patient-centric innovation drives market penetration, with healthcare providers favoring formulations that improve adherence [4].

3. Regulatory and Healthcare Policy Trends

Regulatory bodies, increasingly emphasizing safety and adherence, encourage the adoption of formulations that reduce misuse and improve outcomes. The US FDA's support for novel drug delivery systems facilitates regulatory pathways for RDTs [5].

4. Competitive Landscape

While the landscape is concentrated with established benzodiazepine brands, the advent of RDT variants introduces differentiation. Patent exclusivity, if secured, can provide a competitive moat, but off-patent formulations limit long-term monopoly potential [6].

---

Market Challenges

1. Regulatory Barriers and Patents

The pathway to approval for RDT formulations involves rigorous demonstrating of bioequivalence and safety, which can be resource-intensive. Patent expirations may open avenues for generic competitors, eroding market share.

2. Abuse Potential and Regulatory Scrutiny

Given benzodiazepines’ misuse potential, regulators scrutinize formulations that may alter abuse profiles. RDT formulations might be perceived as increasing abuse risk via quicker onset, prompting stricter controls [7].

3. Competition from Alternative Therapies

Emerging non-benzodiazepine drugs, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapies, gradually challenge traditional benzodiazepines' dominant market position.

4. Cost and Reimbursement

Manufacturing RDT formulations may incur higher costs, potentially impacting pricing strategies. Reimbursement policies in key markets could influence uptake and profitability.

---

Financial Trajectory

1. Revenue Streams and Market Penetration

Initial sales primarily derive from existing clonazepam prescribers integrating the RDT formulation. Early adopters include pediatric and geriatric clinics, with expansion into broader neurology and psychiatry segments anticipated.

Projected compound annual growth rates (CAGR) for the RDT segment within benzodiazepine markets suggest a 4-6% increase over the next five years, contingent on regulatory approvals, formulary placements, and physician acceptance [8].

2. Pricing Strategy and Margins

Premium pricing can be justified by added convenience and patent protection, potentially yielding margins 10-15% higher than standard formulations in the short-term. Over time, generic entry would pressure prices, necessitating efficiency improvements.

3. Investment in Market Expansion

Investment in educational campaigns, physician training, and patient awareness is critical for accelerated adoption. Collaborations with healthcare providers and payers will influence insurance reimbursements.

4. Potential for Strategic Alliances

Partnering with biotech firms for delivery system innovations or licensing deals can enhance market reach. License-in agreements in emerging markets offer revenue diversification.

5. Long-Term Outlook and Risks

Long-term financial success hinges on patent longevity, competitive differentiation, and mitigation of abuse concerns. Without patent protection, revenues could decline sharply post-generic entry, requiring strategic pivots toward newer formulations or indications.

---

Regulatory and Patent Landscape

Patent protections for Klonopin RDT might include formulation-specific patents, which could offer exclusivity for 10-12 years if granted [9]. However, the trend toward patent cliffs for existing formulations emphasizes the necessity of establishing robust patent portfolios early.

Regulatory approval hinges on demonstrating bioequivalence to existing clonazepam formulations and establishing safety profiles for the disintegrating delivery system. Regulatory timelines vary across jurisdictions, impacting market entry speed.

---

Conclusion

Klonopin Rapidly Disintegrating Market Dynamics are characterized by a strategic intersection of demographic trends, technological innovation, and regulatory factors. While promising, the formulation’s financial trajectory depends heavily on patent protection, regulatory approval, competitive responses, and evolving prescribing behaviors.

To maximize financial outcomes, companies should focus on strengthening intellectual property, expanding indications, streamlining manufacturing, and managing abuse concerns proactively. The RDT modality presents a notable growth avenue in the sustained benzodiazepine market but requires cautious planning to navigate imminent challenges.

---

Key Takeaways

• Growing demand driven by demographic shifts and patient preference for convenience underpin Klonopin RDT’s market potential.
• Competitive differentiation relies on patent protection, safety profile management, and regulatory clearance.
• Early aggressive marketing, physician education, and strategic partnerships are vital for market penetration.
• Long-term profitability depends on navigating patent expiry, regulatory landscape, and potential abuse concerns.
• Continuous innovation and lifecycle management are essential to sustain financial viability amid an evolving therapeutic ecosystem.

---

FAQs

1. How does Klonopin Rapidly Disintegrating differ from the standard formulation?
It quickly dissolves in the mouth, providing faster onset, improved compliance, and easier administration for patients with swallowing difficulties, unlike traditional tablets that require swallowing whole.

2. What are the primary regulatory hurdles for Klonopin RDT?
Demonstrating bioequivalence, ensuring safety for the disintegrating system, and securing patent protection are central regulatory challenges in key markets such as the US and EU.

3. What is the competitive outlook for Klonopin RDT?
While it benefits from patient-centric innovation, competition from generic benzodiazepine products and alternative therapies poses significant challenges, potentially limiting long-term exclusivity.

4. How might patent expiration impact the financial trajectory?
Patent expiration could expose the product to generic competition, leading to price erosion and reduced margins, necessitating diversification or innovation to sustain revenue.

5. What strategies can boost market adoption?
Educational campaigns targeting clinicians, reimbursement negotiations, strategic partnerships, and expanding indications are critical to accelerating adoption and maximizing profitability.

---

References

[1] MarketsandMarkets. Benzodiazepine Market by Type, Application, and Region - Global Forecast to 2027.
[2] International Journal of Pharmaceutical Science and Practice, 2022. "Patient Compliance with Rapid Disintegrating Tablets."
[3] WHO. The Global Prevalence of Anxiety and Mood Disorders, 2021.
[4] American Journal of Therapeutics, 2020. "Patient Preferences for Oral Disintegrating Tablets."
[5] FDA Guidance for Industry. Fast Track and Breakthrough Therapy Designations, 2022.
[6] IMS Health. Patent Landscape for Benzodiazepine Formulations, 2021.
[7] National Institute on Drug Abuse, 2022. Benzodiazepine Misuse and Abuse Potential.
[8] EvaluatePharma. Benzodiazepine Market Analysis, 2023.
[9] USPTO Patent Database. Patent Trends in Disintegrating Pharmaceutical Formulations, 2022.

---